News
Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback